Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician.
elderly
elderly oncology
geriatric oncology
head and neck cancer
hypofractionation
radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
08
2021
accepted:
21
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
epublish
Résumé
Radiotherapy (RT) in the head and neck (H&N) site are undoubtedly the most challenging treatments for patients. Older and frail patients are not always able to tolerate it, and there are still no clear guidelines on the type of treatments to be preferred for them. The recommendations for Risk-Adapted H&N Cancer Radiation Therapy during the coronavirus disease 2019 (COVID-19) pandemic provided by the ASTRO-ESTRO consensus statement achieved a strong agreement about hypofractionated RT (HFRT). A systematic literature review was conducted in order to evaluate the feasibility and safety of HFRT for older patients affected by H&N malignancies. A systematic database search was performed on PubMed and Embase according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Original studies, case series, and case reports describing the use of HFRT (with at least 2.2 Gy fractions) in patients with mean age ≥65 years were included. The analysis was based on the type of study, number of patients, mean age, tumor site, histology, performance status (PS), RT details, concomitant chemotherapy (CT), and described clinical outcomes. All the reported doses have been calculated in equivalent dose in 2 Gy fractions (EQD2) and biologically effective dose (BED) using α/β = 10 Gy or α/β = 12 Gy. We selected 17 papers that met the inclusion criteria and divided them in 4 categories: 6 articles analyze HFRT performed twice daily in repeated cycles, 3 once a day in repeated cycles, 4 in alternative days, and the last 4 in consecutive days. HFRT seems to be a good treatment with an acceptable prolonged disease control. In older patients fit for radical treatments, a 55 Gy in 20 fractions regimen can be proposed as a valid alternative to the standard fractionated RT, but there are a multitude of hypofractionated regimens, ranging from single fraction, quad shot, and 1-, 2-, 3-, 4-, and 5-week schedules that all may be appropriate. The correct regimen for a patient depends on many factors, and it represents the result of a more specific and complex decision.
Identifiants
pubmed: 34868976
doi: 10.3389/fonc.2021.761393
pmc: PMC8633531
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
761393Informations de copyright
Copyright © 2021 Piras, Boldrini, Menna, Venuti, Pernice, Franzese, Angileri and Daidone.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Clin Oncol. 2011 Jun;34(3):254-8
pubmed: 20562588
J Geriatr Oncol. 2015 Jul;6(4):272-9
pubmed: 26088748
Lancet Oncol. 2010 Jan;11(1):66-74
pubmed: 19875337
Tumori. 2021 Feb;107(1):26-31
pubmed: 32410505
Ann Oncol. 2014 Nov;25(11):2134-2146
pubmed: 24625455
CA Cancer J Clin. 2019 Nov;69(6):452-467
pubmed: 31390062
Br Med J. 1914 Jun 13;1(2789):1284-6
pubmed: 20767179
Radiother Oncol. 2007 Dec;85(3):456-62
pubmed: 18036689
J Geriatr Oncol. 2021 Apr;12(3):441-445
pubmed: 33097457
BMC Cancer. 2018 Oct 23;18(1):1026
pubmed: 30352576
Head Neck. 2021 Mar;43(3):798-804
pubmed: 33325113
Head Neck. 2016 Apr;38 Suppl 1:E1264-70
pubmed: 26332196
Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1342-51
pubmed: 17241752
Int J Cancer. 2019 Jan 1;144(1):49-58
pubmed: 29978474
J Chemother. 2001 Dec;13(6):648-52
pubmed: 11806627
Cancer Radiother. 2020 Dec;24(8):812-819
pubmed: 33144061
Lancet Oncol. 2012 Sep;13(9):916-26
pubmed: 22877848
Oral Oncol. 2021 Feb;113:105112
pubmed: 33321287
Cancer. 2020 Aug 1;126(15):3426-3437
pubmed: 32478895
Med Oncol. 2019 Jun 12;36(8):68
pubmed: 31190132
Oral Oncol. 2020 Dec;111:105045
pubmed: 33091846
Clin Oncol (R Coll Radiol). 2011 Mar;23(2):141-8
pubmed: 20934860
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):618-627
pubmed: 32302681
Anticancer Res. 2016 Mar;36(3):933-9
pubmed: 26976981
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):272-278
pubmed: 30776451
Head Neck. 2017 Apr;39(4):E55-E60
pubmed: 28170130
Oral Oncol. 2017 Nov;74:142-147
pubmed: 29103743
Oral Oncol. 2015 Oct;51(10):957-62
pubmed: 26282714
Front Oncol. 2018 Jun 11;8:206
pubmed: 29942791
Clin Oncol (R Coll Radiol). 2011 Feb;23(1):34-9
pubmed: 20863676
Head Neck. 2019 Apr;41(4):959-966
pubmed: 30620435
Clin Oncol (R Coll Radiol). 2011 Mar;23(2):149-58
pubmed: 20951012
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):254-266
pubmed: 31128145
Head Neck. 2005 Aug;27(8):659-68
pubmed: 15920748
Clin Interv Aging. 2014 Dec 31;10:117-25
pubmed: 25678781
Radiat Oncol. 2015 Sep 23;10:203
pubmed: 26395876
Radiother Oncol. 2020 Aug;149:181-188
pubmed: 32417345
Radiat Oncol. 2020 May 27;15(1):123
pubmed: 32460865
Clin Oncol (R Coll Radiol). 2010 Dec;22(10):890-1
pubmed: 20584592
Breast J. 2019 Nov;25(6):1206-1213
pubmed: 31359556
Radiother Oncol. 2005 Nov;77(2):137-42
pubmed: 16260054